05/07/2022EMA's CHMP approved a new manufacturing site for the active substance of COVID-19 vaccine Nuvaxovidhttps://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-disease-covid-19/covid-19-latest-updates
Novavax aparece como vacuna disponible en 9.682 centros de vacunación de Estados Unidos, datos actualizados el día 4 de Julio, en la página oficial del CDC.https://data.cdc.gov/Vaccinations/Vaccines-gov-COVID-19-vaccinating-provider-locatio/5jp2-pgawTodas las localizaciones corresponden a CVS Pharmacy, Inc. y aparecen con 0 vacunas en stock.
Oficialmente podemos afirmar que ayer, día 3 de Julio, 3.243 millones de vacunas Covovax salieron de la India rumbo a USA(32.43 Covovax) 03 July 2022https://www.mea.gov.in/vaccine-supply.htm
Novavax Statement on Prototype Vaccine’s Broad Immune Responses and Accelerated Focus on Omicron BA.4/5 as Recommended by the FDA https://ir.novavax.com/Novavax-Statement-on-Prototype-Vaccines-Broad-Immune-Responses-and-Accelerated-Focus-on-Omicron-BA-4-5-as-Recommended-by-the-FDA Novavax is awaiting US emergency use authorization for our prototype COVID-19 vaccine and we are committed to bringing it to market. Clinical data generated to-date demonstrate that this prototype vaccine offers broad immune responses including against circulating variants, such as the Omicron BA.4/5. Novavax is already well underway in our variant program and will accelerate our focus on Omicron BA.4/5, as recommended by FDA in their guidance on June 30th. We expect to have additional preclinical data on Omicron BA.4/5 in the late summer or fall, and expect to be in a position to provide an Omicron-containing vaccine in Q4 of this year. Novavax continues to believe in the importance of vaccines that offer broad immune responses against a variety of variants, given the fact that COVID-19 will continue to evolve.
En principio, hoy Novavax no van a presentar nada de la vacuna específica, ni de la bivalente. Novavax will be presenting data on the use of their Novavax COVID-19 Vaccine, Adjuvated as a booster to address SARS-CoV-2 variants. This vaccine was developed against the prototype virus. https://www.fda.gov/media/159452/download
La importancia de la reunión yo creo que reside en los datos que presente Novavax del booster, de la eficacia contra Omicron y la comparativa con los datos de las otras dos; no espero grandes movimientos ese día tampoco
IDRALo he mirado, son los resultados de las votaciones en la junta de accionistas. No veo nada destacable que explique la subida.https://ir.iderapharma.com/node/17351/htmlSaludos!
